trial
as of 2026-07-01Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCTId NCT05110157
at a glance
Phase 3 · Completed
Enrollment 442 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2025-02-04
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
442 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-11-29
Primary completion
2025-02-04
Eligibility
ALL · 18 Years
Interventions & indications
Drugs
Indications
Sponsors
Neurocrine BiosciencesLead Sponsor
Investigators
1
Clinical Development LeadStudy Director
Sites
87 total
Phoenix, United StatesRogers, United StatesAnaheim, United StatesBellflower, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesLong Beach, United StatesOceanside, United StatesPico Rivera, United StatesRiverside, United StatesSan Diego, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
442
Phase
PHASE3
Primary Completion Date
2025-02-04
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication
investigator